In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1892 News Items found
Lydia Finley
What Cancer Cells Eat: Cancer Metabolism May Hold Key to New Treatments

Biologist Dr. Lydia Finley studies cell metabolism — how cells convert nutrients into the molecules they need to function — in order to better understand cancer and help develop new treatments.
Two women wearing blue MSK volunteer jackets walk smiling down a hospital hallway.
What Happens After Cancer Treatment Ends? Three Survivors Share Their Stories

Read honest stories about the challenges of survivorship from cancer survivors — and learn how MSK continues to care for people long after treatment has ended.
MSK Medical oncologist and liver cancer specialist Dr. Ghassan K. Abou-Alfa
Article
Liver Cancer Progression Slowed by Adding Immunotherapy to TACE

Read about a new treatment that slows the progression of intermediate-risk liver cancer.
Dr. Alexander Drilon
Targeted Drug Selpercatinib Greatly Reduces Risk of Recurrence in Early-Stage Lung Cancer

A clinical trial led by an MSK researcher found that the targeted therapy selpercatinib reduces the risk of recurrence by more than 80% for patients with early-stage non-small cell lung cancers carrying a RET gene fusion.
Andi Straus and her son, Nadav, pose on a hiking trail.
Targeted Therapy Shows Promising Results Against Rare Soft Tissue Sarcoma

A clinical trial led by doctors from MSK has found that abemaciclib — a drug already approved for certain breast cancers — can significantly slow the growth of dedifferentiated liposarcoma, a rare, aggressive soft tissue cancer.
MSK radiation oncologist Nancy Lee
In the Clinic
Low-Dose Radiation Successfully Treats HPV Throat Cancer With Fewer Side Effects

Learn how HPV-related head and neck cancer can be treated with a sharply reduced radiation dose to prevent side effects, sometimes without surgery.
MSK breast cancer specialist Pedram Razavi, MD, PhD.
Article
Latest Research Into Overcoming Resistance to Breast Cancer Targeted Therapies

Learn how MSK's researchers are making important strides in overcoming breast cancer resistance.
An MSK researcher at work in the lab
MSK Research Highlights, May 26, 2026

New MSK research provides structural insights into how cancer cells thwart targeted RAS therapies; uncovers promising combination therapies for a rare childhood brain tumor; uses organoids to provide important clues about what drives pancreatic cancer; takes aim at appendix cancer with new laboratory models; and a develops a new precision tool for targeting cancer's energy factory.
Dr. Shanu Modi speaks with a patient
In the Clinic
FDA Approves Trastuzumab Deruxtecan (T-DXd) for Early-Stage HER2-Positive Breast Cancer

The FDA has approved trastuzumab deruxtecan (T-DXd, Enhertu) for treating early-stage, HER2-positive breast cancer based in part on clinical research led by MSK breast medical oncologist Shanu Modi, MD.
Dr. Alison Schram
FDA Approves Zenocutuzumab for Cholangiocarcinoma Based on MSK-Led Trial

The FDA has approved zenocutuzumab (Bizengri®) for adults with advanced, unresectable, or metastatic cholangiocarcinoma driven by a molecular change called an NRG1 gene fusion, based on a trial led by an MSK investigator.